Results 31 to 40 of about 30,645 (194)
Background Serum hepatitis B virus RNA (HBV RNA) has been reported to be a surrogate marker of intrahepatic cccDNA during nucleos(t)ide analogs therapy.
Xiaomei Wang +10 more
doaj +1 more source
Aims: To evaluate the HBeAg seroconversion rate in real clinical setting and explore its predictors in long-term nucleos(t)ide analogues (NAs) treatment for chronic hepatitis B (CHB).
Weiyan Yu +12 more
doaj +1 more source
Levels of HBV DNA and not HBsAg are associated with biochemical flares after HBeAg seroconversion [PDF]
BACKGROUND: The role of HBsAg levels in predicting subsequent flares in chronic hepatitis B patients after HBeAg seroconversion is not known METHODS: Serum HBsAg and HBV DNA levels were determined in 224 CHB patients at 6-12 months after spontaneous ...
Fung, J +4 more
core +1 more source
BackgroundTissue covalently closed circular DNA (cccDNA) can reflect the activity of HBV replication. However, it is impractical to assess intrahepatic cccDNA in every outpatient.
Yachao Tao +18 more
doaj +1 more source
Sequence analysis of integrated hepatitis B virus DNA during HBeAg-seroconversion
Hepatitis B virus (HBV) integration into the host cell genome occurs early on in infection and reportedly induces pro-oncogenic changes in hepatocytes that drive HCC initiation.
Thomas Tu (606295) +3 more
core +1 more source
Purpose: This study aims to investigate the antiviral effect of polyethylene glycol (PEG)-interferon α-2a and PEG-interferon α-2b treatment on hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) at the 48th week of treatment and the 24th and
Xin Luo +4 more
doaj +1 more source
Objective To investigate the efficiency of pegylated interferon α therapy for patients with HBeAg-positive chronic hepatitis B (CHB) and explore whether liver histopathological features and other factors might influence HBeAg seroconversion.
Cheng-liang Zhu +4 more
core +1 more source
Objectives: To assess off-treatment virological relapse rates and to determine the role of hepatitis B surface antigen (HBsAg) quantification in predicting virological relapse after stopping entecavir (ETV) treatment in patients with hepatitis B e ...
Yuan-wang Qiu +11 more
doaj +1 more source
Background The prevalence of dyslipidemia in China is increasing annually. Current studies suggest that dyslipidemia affects the antiviral efficacy of hepatitis C virus (HCV) therapies, while recent studies suggest that serum lipids influence the ...
Ziqiang Xia +6 more
doaj +1 more source
Spontaneous and 3-, 4-, and 5-year NA treatment-induced HBeAg seroconversion in HBeAg-positive CHB patients.
Lin Cao (294505) +3 more
core +1 more source

